References

Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database

10.1016/s1072-7515(99)00075-7 · 1999 · External reference

The National Cancer Database report on pancreatic, cancer

10.1002/1097-0142(19951101)76:9<1671::aid-cncr2820760926>3.0.co;2-r · 1995 · External reference

Cancer statistics, 2009

10.3322/caac.20006 · 2009 · External reference

Metastatic pancreatic cancer 2008: is the glass less empty?

10.1634/theoncologist.2007-0181 · 2008 · External reference

Advanced pancreatic cancinoma: current treatment and future challenges

10.1038/nrclinonc.2009.236 · 2010 · External reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

10.1200/jco.1997.15.6.2403 · 1997 · External reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

10.1200/jco.2006.07.9525 · 2007 · External reference

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

10.1002/cncr.10323.abs · 2002 · External reference

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

10.1200/jco.2004.12.082 · 2004 · External reference

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial

10.1200/jco.2005.06.023 · 2005 · External reference

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

10.1093/annonc/mdi309 · 2005 · External reference

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

10.1200/jco.2006.07.0201 · 2006 · External reference

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

10.1200/jco.2005.05.1490 · 2006 · External reference

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

10.1038/sj.bjc.6603301 · 2006 · External reference

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

10.1200/jco.2009.24.2446 · 2009 · External reference

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

10.1200/jco.2009.25.4433 · 2010 · External reference

Underrepresentation of patients 65years of age or older in cancer-treatment trials

10.1056/nejm199912303412706 · 1999 · External reference

Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

10.1093/annonc/mdh344 · 2004 · External reference

Prognosis and management strategies of lymphatic neoplasias in the elderly. I. Aggressive non-Hodgkin's lymphomas

10.1159/000011855 · 1998 · External reference

Influence of age on the treatment of limited-stage small-cell lung cancer

10.1200/jco.1996.14.3.821 · 1996 · External reference

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial

10.1093/jnci/94.3.173 · 2002 · External reference

Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases

10.1016/0895-4356(92)90133-8 · 1992 · External reference

Risk adjustment in outcome assessment: the Charlson comorbidity index

10.1055/s-0038-1634956 · 1993 · External reference

Comorbid illness is associated with survival and length of hospital stay in patients with chronic disability

10.1097/00005650-199611000-00004 · 1996 · External reference

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

10.1016/0021-9681(87)90171-8 · 1987 · External reference

Therapeutic options for elderly patients with advanced non-small cell lung cancer

10.1016/j.ctrv.2008.10.008 · 2009 · External reference

Comorbidity and functional status are independent in older cancer patients

10.1200/jco.1998.16.4.1582 · 1998 · External reference

Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer

10.1200/jco.2000.18.13.2529 · 2000 · External reference

Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study

10.1093/annonc/mdi368 · 2005 · External reference

Survival associated with5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer

10.7326/0003-4819-136-5-200203050-00007 · 2002 · External reference

Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: metaanalysis of three trials investigating 5-FU and irinotecan

2006 · External reference

Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a multicenter phase II study

10.1016/s0169-5002(99)00098-7 · 2000 · External reference

Safety profile of gemcitabine

10.1097/00001813-199512006-00005 · 1995 · External reference

Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age

1997 · External reference

Unresolved reference

External reference